Placebo for anacetrapib

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

DyslipidemiaHeterozygous Familial Hypercholesterolemia (HeFH)

Phase 3

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)

CompletedNCT01760460

Merck Sharp & Dohme LLCDyslipidemia

Start: 2013-03-14End: 2015-03-04Updated: 2017-06-01

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)

CompletedNCT01824238

Merck Sharp & Dohme LLCHeterozygous Familial Hypercholesterolemia (HeFH)

Start: 2013-05-31End: 2014-05-31Updated: 2016-04-25

Related Papers

Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia

Atherosclerosis2017-03-1016 citations

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia.

2016-03-259 citations